Skip to main content

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Benson, AB; D'Angelica, MI; Abbott, DE; Anaya, DA; Anders, R; Are, C; Bachini, M; Borad, M; Brown, D; Burgoyne, A; Chahal, P; Chang, DT ...
Published in: J Natl Compr Canc Netw
May 1, 2021

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 1, 2021

Volume

19

Issue

5

Start / End Page

541 / 565

Location

United States

Related Subject Headings

  • Sorafenib
  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Humans
  • Carcinoma, Hepatocellular
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., … Darlow, S. D. (2021). Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(5), 541–565. https://doi.org/10.6004/jnccn.2021.0022
Benson, Al B., Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, et al. “Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 19, no. 5 (May 1, 2021): 541–65. https://doi.org/10.6004/jnccn.2021.0022.
Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541–65.
Benson, Al B., et al. “Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 19, no. 5, May 2021, pp. 541–65. Pubmed, doi:10.6004/jnccn.2021.0022.
Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey J-N, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541–565.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 1, 2021

Volume

19

Issue

5

Start / End Page

541 / 565

Location

United States

Related Subject Headings

  • Sorafenib
  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Humans
  • Carcinoma, Hepatocellular
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis